Health Tip: At Risk for Alzheimer's?

Title: Health Tip: At Risk for Alzheimer's?Category: Health NewsCreated: 8/30/2013 7:35:00 AMLast Editorial Review: 8/30/2013 12:00:00 AM
Source: MedicineNet Alzheimer - Category: Geriatrics Source Type: news

Related Links:

Authors: Forester BP, Rahman AT, Harper DG, Petrides G PMID: 31734085 [PubMed - as supplied by publisher]
Source: The American Journal of Geriatric Psychiatry - Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research
Org. Biomol. Chem., 2019, Accepted Manuscript DOI: 10.1039/C9OB02334H, PaperChun-Xue Yu, Ru-Yue Wang, Feng-Ming Qi, Pan-Jie Su, Yi-Fan Yu, Bing Li, Ye Zhao, Dejuan Zhi, Zhan-Xin Zhang, Dong-Qing Fei Eupulcherol A (1), a novel triterpenoid with an unprecedented carbon skeleton, was isolated fromEuphorbia pulcherrima. Its structure was determined by comprehensive analysis of spectroscopic data, including HRESIMS, 1D and... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Organic and Biomolecular Chemistry - Category: Molecular Biology Authors: Source Type: research
DiscussionMCI prevalence varied among Hispanic/Latino backgrounds, but not as widely as reported in the previous studies. CVD risk and depressive symptoms were associated with increased MCI, whereas APOE4 was not, suggesting alternative etiologies for MCI among diverse Hispanics/Latinos. Our findings suggest that mitigating CVD risk factors may offer important pathways to understanding and reducing MCI and possibly dementia among diverse Hispanics/Latinos.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
The worst possible outcome when developing a clinical therapy is not an early failure. It is a late failure, in the final and most expensive phase III clinical trial, in which the therapy interacts with a sizable patient population, and after a great deal of time and funding have been devoted to the program. This result is far more likely for therapies based on mechanisms that have smaller rather than larger effect sizes, and where that smaller effect size varies from individual to individual for reasons that are not well understood - something that describes all too much of the past few decades of efforts to treat age-rel...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
A large Australian study found no association between cholesterol-lowering statins and memory or thinking problems.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Cholesterol Alzheimer ' s Disease Statins (Cholesterol-Lowering Drugs) Drugs (Pharmaceuticals) Heart Memory Source Type: news
Dr Richard Isaacson on vitamin D supplementation's possible role in combating Alzheimer's dementia.Medscape Neurology
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news
A novel PET imaging technique has uncovered high levels of ischemia in patients...Read more on AuntMinnie.comRelated Reading: PET/MRI sheds light on cerebral vascular risk factors Flortaucipir-PET shows tau accumulation after one TBI PET, MRI show physical activity aids brain health Carbon-11 PET detects brain inflammation after Lyme disease SNMMI: Cerebrovascular risk tied to Alzheimer's disease
Source: Headlines - Category: Radiology Source Type: news
In this study, we use multiple rodent and human brain tissue and neural cell models to demonstrate that CLU is expressed as multiple isoforms that have distinct cellular or subcellular localizations in the brain. Of particular significance, we identify a non-glycosylated 45 kDa CLU isoform (mitoCLU) that is localized to the mitochondrial matrix and expressed in both rodent and human neurons and astrocytes. In addition, we show that rodent mitoCLU is translated from a non-canonical CUG (Leu) start site in Exon 3, a site that coincides with an AUG (Met) in human CLU. Last, w e reveal that mitoCLU is present at the gene and p...
Source: eLife - Category: Biomedical Science Tags: Neuroscience Source Type: research
This randomized clinical trial examines whether 24 months of minocycline treatment can modify cognitive and functional decline in patients with mild Alzheimer disease.
Source: JAMA Neurology - Category: Neurology Source Type: research
Howard and colleagues report a randomized clinical trial in which 554 patients clinically diagnosed with early Alzheimer disease were randomized to 200 mg/d or 400 mg/d of the broad-spectrum antibiotic minocycline or to placebo and followed up for 24 months. Clinical outcomes were a structured Mini-Mental State Examination (MMSE) and the Bristol Activities of Daily Living scale. About 62% of the 200 mg/d minocycline –treated group compared with 64% of the placebo-treated group completed 2 years of treatment; only 29% of the group receiving 400 mg/d of minocycline completed the trial. There was no evidence for efficac...
Source: JAMA Neurology - Category: Neurology Source Type: research
More News: Alzheimer's | Geriatrics | Health